References
- Galazka AM. The immunological basis for immunization series. Module 3: Tetanus. 1993; WHO/EPI/GEN/93.13. World Health Organisation, Geneva.
- Ministry of Health of Turkey. National epidemiological surveillance of vaccine preventable diseases based on laboratory data. Turkish Bull Hyg Exp Biol 2001;58 (Suppl 1)
- Coplu N, Esen B, Gozalan A, Miyamura K, Yoshida I, Kutroglu D, et al. Tetanus antibody assay combining in-house ELISA and particle agglutination test and its serosurvey application in a province in Turkey. Jpn J Infect Dis 2004; 57: 97–102
- Kurtoglu D, Gozalan A, Coplu N, Miyamura K, Morita M, Esen B, , et al Community-based seroepidemiology of tetanus in 3 selected provinces in Turkey. Jpn J Infect Dis 2004;57:10–6.
- General Directorate of Primary Health Care of Ministry of Health, Turkey (2002): The Annual 2001 General Directorate of Primary Health Care and Health Projects General Coordination Unit, Ministry of Health of Turkey, Ankara.
- Maple PA, Jones JS, Wall EC, Vyse A, Edmunds WJ, Andrews NJ, et al. Immunity to diphtheria and tetanus in England and Wales. Vaccine 2000; 19: 167–73
- Stark K, Schönfeld C, Barg J, Molz B, Vornwald A, Bienzle U. Seroprevalance and determinants of diphtheria, tetanus and poliomyelitis antibodies among adults in Berlin, Germany. Vaccine 1999; 17: 844–50
- Langue J, Matisse N, Pacoret P, Undreiner F, Boisnard F, Soubeyrand B, et al. Persistence of antibodies at 5–6 y of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5–6 y of age. Vaccine 2004; 22: 1406–14
- De Melker HE, van den Hof S, Berbers GA, Nagelkerke NJ, Rumke HC, Conyn-van Spaendonck MA. A population-based study on tetanus antitoxin levels in the Netherlands. Vaccine 1999; 18: 100–8
- Ozturk A, Goahmetoglu S, Erdem F, Mysguroglu AS. Tetanus antitoxin levels among adults over 40 y of age in central Anatolia, Turkey. Clin Microbiol Infect 2003; 9: 33–8
- Ergonul O, Sozen T, Tekeli E. Immunity to tetanus among adults in Turkey. Scand J Infect Dis 2001; 33: 728–30
- Soyletir G, Yagci A, Topkaya A, Ciragil P. Detection of anti-tetanus antibodies in a Turkish population. Tropical Doctor 1999; 29: 161–2
- Steger MM, Maczek C, Berger P, Grubeck-Loebenstein B. The immune response to tetanus in elderly people: shortened immunological memory affects the duration of protection. Wien Klin Wochenschr 1997; 109: 767–70
- Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW, Virella G. A population-based serological survey of immunity to tetanus in the United States. N Engl J Med 1995; 332: 761–6
- Heath TC, Smith W, Capon AG, Hanlon M, Mitche P. Tetanus immunity in an older Australian population. Med J Aust 1996; 164: 593–6
- Sutter RW, Cochi SL, Brink EW, Sirotkin BI. Assessment of vital statistics and surveillance data for monitoring tetanus mortality, United States, 1979–1984. Am J Epidemiol 1990; 131: 132–42
- Ergonul O, Erbay A, Eren S, Dokuzoguz B. Analysis of the case fatality rate of tetanus among adults in a tertiary hospital in Turkey. Eur J Clin Microbiol Infect Dis 2003; 22: 188–90